PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-28.92%
Negative ROE while Drug Manufacturers - Specialty & Generic median is -19.06%. Seth Klarman would investigate if capital structure or industry issues are at play.
-23.20%
Negative ROA while Drug Manufacturers - Specialty & Generic median is -6.21%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-19.94%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is -4.37%. Seth Klarman would investigate whether a turnaround is viable.
28.00%
Gross margin near Drug Manufacturers - Specialty & Generic median of 30.06%. Charlie Munger might attribute it to standard industry practices.
-337.04%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is -25.68%. Seth Klarman would look for a path to operational turnaround.
-424.93%
Negative net margin while Drug Manufacturers - Specialty & Generic median is -26.04%. Seth Klarman would see if cost cuts or revenue growth can fix losses.